This article refers to:
Correction to: Prospect & progress of venetoclax for treating chronic lymphocytic leukaemia
Chitalia, A and Ujjani, C. Prospect & progress of venetoclax for treating chronic lymphocytic leukaemia. Expert Opin Orphan Drugs. 2016.
http://dx.doi.org/10.1080/21678707.2016.1230059
When the above article was first published online, the Declaration of Interest was missing information. This has now been corrected in the online version, so that it now reads “C Ujjani has provided advisory board and speaking services for Abbvie and advisory board services for Genentech”.